Preparing a GLP-1 and CKD talk. So many questions left.
What about patients with proteinuria but without obesity or diabetes?
What about obese patients with diabetes but without proteinuria?
Have we looked into body composition and CKD risk instead of BMI or kg body weight only?
Membranous nephropathy (MN) in the transplant is-
1. Recurrent, mostly PLA2R+
or
2. De novo, associated with antibody mediated rejection, mostly FAT1+
We present an unusual case of de novo MN, which was Exostosin + & negative for all other antigens
https://t.co/JnfKAJPJRD
@sofie_dhaese views to manage infections in patients with renal failure
#LIVES2023@ESICM
Important messages here are:
✅dose to kill different from dose to avoid selection of resistant strains
✅attractive option: reach the maximum tolerated dose! How to manage that?
👏 Great talk @sofie_dhaese ➕➕➕
My take home message here is crystal clear:
🙏Don’t decrease the dose only because the patient has renal failure! The risk of undertreatment is important and the risk of dose dependent toxicity unsure!
#LIVES2023@ESICM
Up to date review on the management of IgA nephropathy.
Treatment of IgA nephropathy: a rapidly evolving field : Journal of the American Society of Nephrology https://t.co/4UtE9IRXK4
📢Publication alert: American Society of Hematology 2023 Guidelines for Management of Venous Thromboembolism: Thrombophilia Testing https://t.co/NkpneG3hdQ
Oral anticoagulation in AF patients with advanced CKD. Yes, no, or maybe a little bit? Looking forward to SACK trial and @TRACK_trial! https://t.co/NI74z0B60K
First day as a nephrologist back in Belgium and guess what, the patient comes from the Netherlands! Fortunately I’ve mastered the Dutch accent (and many other things) during my stay @radboudumc dept of Nephrology. Big thanks and hope to visit Nijmegen again soon!!
🚨Register now for our next Journal Club!
Topic: Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D
https://t.co/6GpWJ8mMMd
📅Thursday 30 March
🕖5 to 6 PM CEST
🆓registration: https://t.co/6SGNH69Ucd
#RT@aHUSAllianceAct: RT @aHUSUKvoice: Treatment withdrawal for #aHUS when and how? Big questions needing big answers. @KIReports https://t.co/6xRfsMKa1l
👇great #NephJC on new data that piptazo isn't nephrotoxic👏
*both* cefepime & metronidazole can promote delirium (new section on metronidazole-induced encephalopathy @ IBNCC https://t.co/yNw7D3ZdvM)
changing from piptazo to cefepime+metronidazole is *not* good for the brain🧠
Both Piperacillin & Tazobactam are substrates for OAT1&3, the organic anion transporters, & Vancomycin suppresses expression of these pumps. Is rise in creatinine reflective of true renal injury? #NephJC
⚡️Are you a nephrology fellow or an early career nephrologist?
GlomCon accepts applications for the third class of its virtual glomerular disease fellowship.
Work with an elite group of expert faculty. Learn, teach and network!
Apply now at https://t.co/95VwkB6I3H